The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils.
Leif AntonschmidtDirk MatthesRiza DervişoğluBenedikt FriegChristian DienemannAndrei LeonovEvgeny NimerovskyVrinda SantSergey RyazanovArmin GieseGunnar F SchröderStefan BeckerBert L de GrootChristian GriesingerLoren B AndreasPublished in: Nature communications (2022)
Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synuclein fibrils and anle138b, a clinical drug candidate for disease modifying therapy in neurodegeneration and a promising scaffold for positron emission tomography tracer design. We used nuclear magnetic resonance spectroscopy and the cryogenic electron microscopy structure of α-synuclein fibrils grown in the presence of lipids to locate anle138b within a cavity formed between two β-strands. We explored and quantified multiple binding modes of the compound in detail using molecular dynamics simulations. Our results reveal stable polar interactions between anle138b and backbone moieties inside the tubular cavity of the fibrils. Such cavities are common in other fibril structures as well.
Keyphrases
- positron emission tomography
- small molecule
- electron microscopy
- molecular dynamics simulations
- computed tomography
- pet imaging
- protein protein
- pet ct
- molecular docking
- binding protein
- stem cells
- single molecule
- high resolution
- genome wide
- mesenchymal stem cells
- dna methylation
- transcription factor
- ionic liquid
- dna binding
- cell therapy